The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

Completed · Phase 4

Conditions studied: Healthy

In brief

The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy.

Key facts

Study ID

NCT01112670

Run by

University of Colorado, Denver

People needed

33

Starts

2009-11-01

Expected to finish

2011-07-01

Last updated by the study team

2013-01-24

Who can join

Age: 21 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and women between 21 to 60 years of age will be recruited to participate in this study.
• Subjects will be eligible if metabolic, renal, hepatic, and hematological laboratory tests are within normal limits.

You may not qualify if…

• Subjects will be excluded from the study if they have a current or past history of cardiovascular, hepatic, endocrine (e.g., diabetes), renal, pancreatic, gastrointestinal, pulmonary, immunologic, hematologic, or neurologic disease.

Where it is running

• University of Colorado Denver — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.